These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 32284734)

  • 1. The Role of Clopidogrel in 2020: A Reappraisal.
    Patti G; Micieli G; Cimminiello C; Bolognese L
    Cardiovasc Ther; 2020; 2020():8703627. PubMed ID: 32284734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence.
    Davis KA; Miyares MA; Dietrich E
    Am J Health Syst Pharm; 2015 Oct; 72(19):1623-9. PubMed ID: 26386103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials.
    Kheiri B; Osman M; Abdalla A; Haykal T; Swaid B; Ahmed S; Chahine A; Hassan M; Bachuwa G; Al Qasmi M; Bhatt DL
    J Thromb Thrombolysis; 2019 Feb; 47(2):233-247. PubMed ID: 30511260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical use of clopidogrel.
    Sarafoff N; Byrne RA; Sibbing D
    Curr Pharm Des; 2012; 18(33):5224-39. PubMed ID: 22724411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing Benefits and Risks of Oral Antiplatelet Strategies in patients With Coronary Artery Diseases: An Evolving Issue.
    De Luca L; Gragnano F; Calabrò P; Huber K
    Curr Probl Cardiol; 2023 Dec; 48(12):102025. PubMed ID: 37553063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined antiplatelet therapy: still a sweeping combination in cardiology.
    Manolis AS; Manolis TA; Papadimitriou P; Koulouris S; Melita H
    Cardiovasc Hematol Agents Med Chem; 2013 Jun; 11(2):136-67. PubMed ID: 23597106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
    Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N
    Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ticagrelor versus clopidogrel on platelet reactivity measured by thrombelastography in patients with minor stroke or TIA.
    Yang Y; Chen W; Pan Y; Yan H; Meng X; Liu L; Wang Y; Wang Y
    Aging (Albany NY); 2020 Oct; 12(20):20085-20094. PubMed ID: 33065552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
    Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New opportunities to optimize antithrombotic therapy for secondary stroke prevention.
    Kim AS; Easton JD
    Int J Stroke; 2019 Apr; 14(3):220-222. PubMed ID: 30722755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
    Clemmensen P; Dridi NP; Holmvang L
    Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent P2Y12 inhibitors versus clopidogrel to predict adherence to antiplatelet therapy after an acute coronary syndrome: insights from IDEAL-LDL.
    Kourti O; Konstantas O; Farmakis IΤ; Zafeiropoulos S; Psarakis G; Vrana E; Baroutidou A; Graidis S; Touriki AV; Tsolakidis C; Spyridaki K; Psathas T; Daniilidou A; Karvounis H; Giannakoulas G
    Rev Cardiovasc Med; 2022 Mar; 23(3):81. PubMed ID: 35345248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis.
    Ding L; Peng B
    Eur J Neurol; 2018 Oct; 25(10):1276-1284. PubMed ID: 29855121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
    Gunarathne A; Hussain S; Gershlick AH
    Expert Rev Cardiovasc Ther; 2016 Nov; 14(11):1215-1226. PubMed ID: 27701930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Parker WA; Storey RF
    Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Status of Antiplatelet Therapy in Acute Coronary Syndrome.
    Dash D
    Cardiovasc Hematol Agents Med Chem; 2015; 13(1):40-9. PubMed ID: 26245659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease.
    Lettino M; Leonardi S; De Maria E; Halvorsen S
    Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):61-70. PubMed ID: 28618904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.